Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPA Exposure and Conversion to Mycophenolate Sodium in Renal Transplant
NCT01822483Phase 4Completed
- Sponsor
- Santa Casa de Porto Alegre
- Start
- Apr 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mycophenolate sodium in kidney transplant rejection (2 arms), sponsored by Santa Casa de Porto Alegre. Primary endpoint: Frequency of renal transplants recipients taking mycophenolate mofetil (MMF) with MPA AUC below target level (30mcg*h ml-1). Started Apr 2013; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01822483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01822483.